CJC-1295 (no DAC)vsEnclomiphene

CJC-1295 (no DAC), also known as Mod GRF 1-29, is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH). Four amino acid substitutions (at positions 2, 8, 15, and 27) have been made to increase resistance to enzymatic degradation while preserving full biological activity at the GHRH receptor (GHRH-R), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary.

When CJC-1295 binds the GHRH receptor, it activates the Gs alpha subunit, which stimulates adenylyl cyclase to produce cyclic AMP (cAMP). Rising cAMP levels activate protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein) and other transcription factors that drive GH gene expression and secretion. Importantly, this mechanism preserves the natural pulsatile pattern of GH release because it works within the existing hypothalamic-pituitary feedback loop — somatostatin still provides inhibitory regulation between pulses.

The key advantage of the no-DAC version over the DAC version is this preservation of pulsatility. Because its half-life is approximately 30 minutes, it produces a discrete GH pulse that rises and falls naturally, mimicking the body's own secretory pattern. This pulsatile pattern is believed to be physiologically superior to sustained elevation because GH receptor sensitivity is maintained between pulses, and the liver's IGF-1 production response is optimized by intermittent rather than continuous GH stimulation. This is why CJC-1295 (no DAC) is often preferred by practitioners despite requiring more frequent dosing.

Enclomiphene is the trans-stereoisomer of clomiphene citrate, a selective estrogen receptor modulator (SERM). Clomiphene (Clomid) contains a roughly equal mixture of two geometric isomers: enclomiphene (trans) and zuclomiphene (cis). Enclomiphene is the pharmacologically desired isomer for testosterone elevation because it acts as a pure estrogen receptor antagonist in the hypothalamus and pituitary, while zuclomiphene has mixed agonist/antagonist activity that can cause unwanted estrogenic effects and has a much longer half-life (weeks), accumulating with chronic dosing.

Enclomiphene competitively binds to estrogen receptors (ERα) in the hypothalamus and anterior pituitary gland, blocking the binding of circulating estradiol. Normally, estradiol exerts negative feedback on the hypothalamic-pituitary axis: estradiol binding to ERα in the hypothalamus reduces GnRH pulse frequency and amplitude, while estradiol binding in the pituitary reduces gonadotroph sensitivity to GnRH. By blocking these receptors, enclomiphene removes the negative feedback signal — the hypothalamus 'perceives' low estrogen levels regardless of actual estradiol concentrations and responds by increasing GnRH pulse frequency. The pituitary, also freed from estrogen-mediated suppression, responds more robustly to each GnRH pulse, producing increased LH and FSH secretion.

Elevated LH stimulates Leydig cells in the testes to produce more testosterone (via the LHCGR/cAMP/StAR steroidogenic pathway), while elevated FSH stimulates Sertoli cells to support spermatogenesis. This is the critical advantage of enclomiphene over exogenous testosterone replacement: it raises endogenous testosterone production through the natural HPG axis while preserving (and potentially enhancing) fertility. Exogenous testosterone, by contrast, suppresses LH/FSH through negative feedback, causing testicular atrophy and often azoospermia. The 10-hour half-life of enclomiphene allows once-daily dosing, and its pure antagonist profile at ERα avoids the estrogenic side effects (hot flashes, visual disturbances, mood changes) that zuclomiphene contributes in mixed clomiphene formulations.